Ma Y, Huang Y, Hu F, Shu K
Int J Mol Med. 2024; 54(5).
PMID: 39301636
PMC: 11414527.
DOI: 10.3892/ijmm.2024.5426.
Okamoto M, Yamaguchi S, Sawaya R, Echizenya S, Ishi Y, Kaneko S
Biomed Res Int. 2024; 2024:2973407.
PMID: 38449509
PMC: 10917478.
DOI: 10.1155/2024/2973407.
Staedtke V, Gray-Bethke T, Liu G, Liapi E, Riggins G, Bai R
Neurooncol Adv. 2022; 4(1):vdab184.
PMID: 35118381
PMC: 8807082.
DOI: 10.1093/noajnl/vdab184.
Arpa D, Parisi E, Ghigi G, Cortesi A, Longobardi P, Cenni P
Front Oncol. 2021; 11:643469.
PMID: 33859944
PMC: 8042328.
DOI: 10.3389/fonc.2021.643469.
Bi J, Chowdhry S, Wu S, Zhang W, Masui K, Mischel P
Nat Rev Cancer. 2019; 20(1):57-70.
PMID: 31806884
DOI: 10.1038/s41568-019-0226-5.
Widespread gene transfer to malignant gliomas with In vitro-to-In vivo correlation.
Negron K, Khalasawi N, Lu B, Ho C, Lee J, Shenoy S
J Control Release. 2019; 303:1-11.
PMID: 30978431
PMC: 6579670.
DOI: 10.1016/j.jconrel.2019.04.010.
Hypoxia-inducible factor 2α: a novel target in gliomas.
Renfrow J, Soike M, Debinski W, Ramkissoon S, Mott R, Frenkel M
Future Med Chem. 2018; 10(18):2227-2236.
PMID: 30089425
PMC: 6479274.
DOI: 10.4155/fmc-2018-0163.
Lesion magnetic susceptibility response to hyperoxic challenge: A biomarker for malignant brain tumor microenvironment?.
Ozbay P, Stieb S, Rossi C, Riesterer O, Boss A, Weiss T
Magn Reson Imaging. 2017; 47:147-153.
PMID: 29221966
PMC: 5831359.
DOI: 10.1016/j.mri.2017.12.004.
Investigation of hypoxia conditions using oxygen-enhanced magnetic resonance imaging measurements in glioma models.
Fan Q, Ying Tang C, Gu D, Zhu J, Li G, Wu Y
Oncotarget. 2017; 8(19):31864-31875.
PMID: 28418866
PMC: 5458254.
DOI: 10.18632/oncotarget.16256.
Hyperbaric oxygen therapy sensitizes nimustine treatment for glioma in mice.
Lu Z, Ma J, Liu B, Dai C, Xie T, Ma X
Cancer Med. 2016; 5(11):3147-3155.
PMID: 27734611
PMC: 5119970.
DOI: 10.1002/cam4.851.
Hyperbaric oxygen as an adjunctive therapy in treatment of malignancies, including brain tumours.
Stepien K, Ostrowski R, Matyja E
Med Oncol. 2016; 33(9):101.
PMID: 27485098
PMC: 4971045.
DOI: 10.1007/s12032-016-0814-0.
Cell cycle progression in glioblastoma cells is unaffected by pathophysiological levels of hypoxia.
Richards R, Jenkinson M, Haylock B, See V
PeerJ. 2016; 4:e1755.
PMID: 26966676
PMC: 4782743.
DOI: 10.7717/peerj.1755.
Redox homeostasis protects mitochondria through accelerating ROS conversion to enhance hypoxia resistance in cancer cells.
Li P, Zhang D, Shen L, Dong K, Wu M, Ou Z
Sci Rep. 2016; 6:22831.
PMID: 26956544
PMC: 4783784.
DOI: 10.1038/srep22831.
Stress Response Leading to Resistance in Glioblastoma-The Need for Innovative Radiotherapy (iRT) Concepts.
Combs S, Schmid T, Vaupel P, Multhoff G
Cancers (Basel). 2016; 8(1).
PMID: 26771644
PMC: 4728462.
DOI: 10.3390/cancers8010015.
Bcl-2 family member Mcl-1 expression is reduced under hypoxia by the E3 ligase FBW7 contributing to BNIP3 induced cell death in glioma cells.
Chen Y, Henson E, Xiao W, Shome E, Azad M, Burton T
Cancer Biol Ther. 2015; 17(6):604-13.
PMID: 26467103
PMC: 4990400.
DOI: 10.1080/15384047.2015.1095399.
Evaluation of hypoxia with copper-labeled diacetyl-bis(N-methylthiosemicarbazone).
Lapi S, Lewis J, Dehdashti F
Semin Nucl Med. 2015; 45(2):177-85.
PMID: 25704389
PMC: 4339100.
DOI: 10.1053/j.semnuclmed.2014.10.003.
Intraoperative visualization of cerebral oxygenation using hyperspectral image data: a two-dimensional mapping method.
Mori M, Chiba T, Nakamizo A, Kumashiro R, Murata M, Akahoshi T
Int J Comput Assist Radiol Surg. 2014; 9(6):1059-72.
PMID: 24737109
DOI: 10.1007/s11548-014-0989-9.
Bringing the heavy: carbon ion therapy in the radiobiological and clinical context.
Schlaff C, Krauze A, Belard A, OConnell J, Camphausen K
Radiat Oncol. 2014; 9(1):88.
PMID: 24679134
PMC: 4002206.
DOI: 10.1186/1748-717X-9-88.
The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities.
Walsh J, Lebedev A, Aten E, Madsen K, Marciano L, Kolb H
Antioxid Redox Signal. 2014; 21(10):1516-54.
PMID: 24512032
PMC: 4159937.
DOI: 10.1089/ars.2013.5378.
(62)Cu-diacetyl-bis (N(4)-methylthiosemicarbazone) PET in human gliomas: comparative study with [(18)F]fluorodeoxyglucose and L-methyl-[(11)C]methionine PET.
Tateishi K, Tateishi U, Nakanowatari S, Ohtake M, Minamimoto R, Suenaga J
AJNR Am J Neuroradiol. 2013; 35(2):278-84.
PMID: 23928140
PMC: 7965738.
DOI: 10.3174/ajnr.A3679.